Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled crossover study of BGC20-1531 in acute migraine
2009-010862-43Phase 2Terminated
- Sponsor
- BTG
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BGC20-1531 in migraine (3 arms), sponsored by BTG. Primary endpoints: Headache response at 2 hours post-dose and Headache intensity at 2 hours post-dose. Started Apr 2009; status: terminated.
02
Drugs
BGC20-1531
03
Conditions
migraine
Beyond the preview
Go deeper on 2009-010862-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010862-43.